Objective Patients with systemic sclerosis–associated interstitial lung disease (SSc‐ILD) are
thought to have the greatest decline in lung function (forced vital capacity [FVC]% predicted) …

Objective To determine the prognostic value of pulmonary function test (PFT) trends at 1 and
2 years in interstitial lung disease (ILD) associated with systemic sclerosis (SSc). Methods …

Objective To assess associations between the extent of fibrotic interstitial lung disease (ILD)
and forced vital capacity (FVC) at baseline and change in FVC over 52 weeks in patients …

Objective To identify baseline characteristics of patients with scleroderma‐related interstitial
lung disease (SSc‐ILD) that could serve as predictors of the most favorable response to 12 …

Objectives The aim of this study was to identify risk factors of percent predicted forced vital
capacity (ppFVC) decline in patients with SSc-associated interstitial lung disease (SSc-ILD) …

Objective. Clinically meaningful change in systemic sclerosis (SSc) related interstitial lung
(SSc-ILD) disease is unknown. The aim of this study was to quantify change in pulmonary …

Objectives To identify overall disease course, progression patterns and risk factors
predictive for progressive interstitial lung disease (ILD) in patients with systemic sclerosis …

Background Radiographic end points commonly are included in therapeutic trials for
systemic sclerosis (SSc)-interstitial lung disease (ILD); however, the relationship between …

Rationale: The Scleroderma Lung Study II (SLS II) demonstrated significant improvements in
pulmonary function and dyspnea at 24 months compared with baseline when patients with …

Objective To assess survival and identify predictors of survival in patients with systemic
sclerosis-interstitial lung disease (SSc-ILD) who participated in the Scleroderma Lung …